88
Participants
Start Date
April 8, 2011
Primary Completion Date
March 1, 2013
Study Completion Date
September 1, 2014
OSI-906
As of 01 March 2013, OSI-906 is no longer being administered
Erlotinib
Erlotinib administered orally
Placebo
As of 01 March 2013, the matching placebo is no longer being administered
Pamela Youde Nethersole Eastern Hospital, Chai Wan
Memorial Sloan Kettering Cancer Center, New York
National Cancer Institute, Phayathai
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
Medical University of South Carolina, Charleston
University of Tennessee Cancer Institute, Memphis
Cleveland Clinic Florida, Weston
H. Lee Moffitt Cancer Center and Research Institute, Tampa
Vanderbilt University Medical Center, Nashville
Khon Kaen University, Khon Kaen
Karmanos Cancer Institute, Detroit
Maharaj Nakorn Chiangmai, Chiang Mai
Northwestern Memorial Hospital, Chicago
Rush University Medical Center, Chicago
Songklanagarind Hospital, Prince of Songkla University, Songkhla
University of California, San Diego/Moores Cancer Center, La Jolla
Swedish Cancer Institute, Seattle
Seattle Cancer Care Alliance University of Washington, Seattle
Samsung Medical Center, Seoul
Korea University Anam Hospital, Seoul
Asan Medical Center, Songpa-gu
Oncocare Cancer Center, Singapore
Johns Hopkins Singapore International Medical Centre, Singapore
Chonnam National University Hwasun Hospital, Ilsimri
Juravinski Cancer Centre, Hamilton
London Regional Cancer Program, London
Princess Margaret Hospital, Toronto
Jewish General Hospital, Montreal
Seoul National University Bundang Hospital, Seongnam-si
Lead Sponsor
Astellas Pharma Inc
INDUSTRY